A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found.

A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found.

Because of that, we have done studies that suggested that Herceptin added to chemotherapy in the setting of metastatic breast cancer can also lead to an improvement in breast cancer.

This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. Women with a type of breast cancer referred to as HER-2 positive are ...

Combining the molecularly targeted therapy Herceptin with chemotherapy in women with early stage breast cancer significantly improves disease-free survival for patients with a specific genetic ...

One common treatment for those with HER2-positive breast cancer begins with one or more chemotherapy drugs in addition to trastuzumab, which is an anti-HER2 antibody.

Results: Trastuzumab trough levels were more than 20 μg/mL by the end of cycle 1. The half-life of trastuzumab was estimated to be 18 to 27 days, although this may be an underestimate. The combination ...

Sept. 1, 2005 — The U.S. Food and Drug Administration (FDA) and Genentech, Inc., have warned healthcare professionals via letter of study data linking trastuzumab (Herceptin) therapy to a ...

A new study released this Wednesday revealed that breast cancer that is highly aggressive but caught early could be best treated with a combination of Herceptin and chemotherapy. UCLA researchers ...

Patients with metastatic HER2-positive gastric or gastroesophageal junction (GEJ) cancer saw improvements in progression-free survival (PFS, the time a patient lives following treatment without a ...

Herceptin plus chemotherapy showed numerical improvements in overall survival (OS) and progression-free survival (PFS) for HER2-positive gastric and gastroesophageal junction (GEJ) cancers, although ...

A trastuzumab biosimilar was ... examined 102 patients 18 years or older with HER2 overexpression or HER2-amplified AGC who received first-line trastuzumab-based chemotherapy between February 2011 ...